In vitro studies revealed that bone marrow-derived macrophages treated with Dabrafenib produced significantly less TNFα compared to vehicle-treated cells, and thus the authors argue for a model in which Dabrafenib limits stroke injury by reducing cell death, DAMP production, and macrophage/microglia driven TNFα production. The gene discussed is TNF; the disease is stroke disorder.